CANTOS Trial Advances Inflammatory Hypothesis of Coronary Artery Disease

PCSK9 Inhibitors Outcomes Data: Definitive CV Protection

Reduced All-Cause Death Suggests SGLT-2 Inhibitors May Be Part of New Anti-Diabetes Standard

Upward PCSK9 Inhibitor Dose Titration Uncommonly Required to Reach Goal in Challenging Patients

PCSK9 Inhibitors Required to Reach LDL-C Goals in Many High-risk Patients

Efficacy and Safety of PCSK9 Inhibitors Now Measured In Years with No Change in Scale of Clinical Benefit

Increasing NT-proBNP Isolated as Surrogate for Adverse Outcomes in Heart Failure

PCSK9 Inhibitors Show Similar Efficacy in Diabetics as in Other High-Risk Groups

SPRINT Trial: Mortality Benefit Associated with Intensive Blood Pressure Control

Debating North American Cholesterol Guidelines and the Role of PCSK9 Inhibitors

PCSK9 Inhibitor Achieves Persistent LDL-C Control and Sustained Safety in a Challenging Population